Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies
International Journal of Molecular Sciences · 22.05.2026 · 27 (11) · 4657
DOI: 10.3390/ijms27114657 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2026. Verfasst von Hatice Terzi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Department of Hematology, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye. Hauptthemen laut MEDLINE: Apigenin, Proto-Oncogene Proteins c-akt, Signal Transduction, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hematologic malignancies are driven by dysregulated growth and survival signaling pathways that promote proliferation, treatment resistance, and disease progression. Naturally derived compounds targeting multiple oncogenic pathways with low toxicity have gained interest. Apigenin, a dietary flavonoid, shows anticancer activity in solid tumors, but its molecular effects in hematologic malignancies remain unclear. The antineoplastic effects of apigenin were evaluated in K562 (chronic myeloid leukemia) and DOHH2 (B-cell lymphoma) cell lines. Cell viability was assessed using the CCK-8 assay. L929 (mouse fibroblast) cells were included to evaluate selectivity. EGFR, MAPK, PI3K, NF-κB, caspase-3, and caspase-7 levels were measured by ELISA. Apoptosis and cell cycle distribution were analyzed by flow cytometry. Apigenin reduced cell viability in a dose-dependent manner, with IC50 values of 84.14 μM (K562) and 70.11 μM (DOHH2). It suppressed EGFR, MAPK, PI3K, and NF-κB signaling and increased the caspase-3 and caspase-7 levels (p < 0.001). Flow cytometry showed S-phase arrest and increased apoptosis. L929 cells showed limited reduction in viability at higher concentrations. Apigenin exerts antiproliferative and pro-apoptotic effects via inhibition of the EGFR/MAPK and PI3K/Akt pathways and activation of caspase-mediated apoptosis. Lower sensitivity in L929 cells suggests relative selectivity, supporting further in vivo and clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Department of Hematology, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye.
- Department of Internal Medicine, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye.
- Department of Therapy and Rehabilitation, Vocational School of Health Services, Sivas Cumhuriyet University, 58140 Sivas, Türkiye.
- Department of Medical Genetics, Faculty of Medicine, Erciyes University, 38280 Kayseri, Türkiye.
- Department of Family Medicine, Sivas Provincial Health Directorate, 58080 Sivas, Türkiye.
- Laboratory and Veterinary Health Program, Health Services Vocational School, Osmaniye Korkut Ata University, 80000 Osmaniye, Türkiye.
ORCID-Profile: Hatice Terzi, Mustafa Eymen Kontaş, Ali Güngör
Zitieren
APA
Terzi, H., Taştemur, Ş., Öztürk, A., Başgöz Karaguş, N., Kontaş, M. E., Mahmutoğlu, O., Güngör, A., & Şencan, M. (2026). Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies. International Journal of Molecular Sciences, 27(11), 4657. https://doi.org/10.3390/ijms27114657
Vancouver
Terzi H, Taştemur Ş, Öztürk A, Başgöz Karaguş N, Kontaş ME, Mahmutoğlu O, et al. Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies. International Journal of Molecular Sciences. 2026;27(11):4657. doi:10.3390/ijms27114657
BibTeX
@article{Terzi2026,
author = {Terzi, Hatice and Taştemur, Şeyma and Öztürk, Ayşegül and Başgöz Karaguş, Neslihan and Kontaş, Mustafa Eymen and Mahmutoğlu, Onur and Güngör, Ali and Şencan, Mehmet},
title = {Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {11},
pages = {4657},
doi = {10.3390/ijms27114657}
}
EUVIMED